Published May 2, 2021, 2:04 PM
Recognizing that only 1,000 out of 4,000 children diagnosed with cancer receive proper care and medication, the Department of Science and Technology-Philippine Council for Health Research and Development (DOST-PCHRD) has vowed its unwavering support to the Aruga sa Batang may Cancer (ABC) Initiative that seeks to provide a web-based pediatric palliative care service in the country.
ARUGA sa Batang May Cancer (ABC) Inititative. (Screenshot from the DOSTv Facebook page)
“The DOST-PCHRD continues to support the “Aruga sa Batang may Cancer (ABC) Initiative program that aims to alleviate health burden among pediatric patients diagnosed with cancer through the development and implementation of a website focused on the delivery of palliative care services,” DOST Secretary Fortunato “Boy” T. de la Peña said on the DOSTv Facebook page on Friday, April 30.
Published April 30, 2021, 5:10 PM
Due to insufficient scientific evidence, the Department of Health (DOH) and the Food and Drug Administration (FDA) on Friday, April 30, reiterated that they do not recommend the use of antiparasitic drug Ivermectin for the treatment of the coronavirus disease (COVID-19).
DOH/MB
In a joint statement, the DOH and FDA emphasized that the agencies have always been consistent in their guidance to the public, and echoed that to date, Ivermectin is not approved for the treatment of COVID-19.
“We have said this many times before and we will say it again. We do not recommend the use of Ivermectin for the prevention and treatment of COVID-19 as the benefits of this antiparasitic drug for this purpose has not been established. President Rodrigo Duterte has also ordered the Department of Science and Technology – Philippine Council for Health Research and Development (DOST PCHRD) to conduct a clinical trial to test the efficacy of ivermectin against COVID
The head of the Philippine Society for Microbiology and Infectious Diseases (PSMID) said there is "insufficient evidence at this time to recommend for or against the use of Ivermectin among mild to moderate coronavirus disease (COVID-19) patients."
Philippine Society for Microbiology and Infe
DOST eyes ivermectin trial in NCR quarantine facilities by May
enablePagination: false
endIndex:
Metro Manila (CNN Philippines, April 29) The national government is finalizing details of the clinical trial on the antiparasitic drug ivermectin since there is still no evidence it is effective against COVID-19.
Dr. Jaime Montoya, chief of the Department of Science and Technology-Philippine Council for Health Research and Development (DOST-PCHRD), said they are targeting to start the trial by end of May or first week of June.
Over 1,200 mild to moderate COVID-19 patients undergoing isolation in quarantine facilities could participate in the trial, but the number could eventually go up. The clinical trial - personally ordered by President Rodrigo Duterte - could run for six months or less, but it should be completed before yearend.
Published April 29, 2021, 4:21 PM
The Department of Science and Technology (DOST) called on Thursday, April 29, its previous scholars, Filipino scientists, and those experts in the fields of microbiology, molecular biology and biochemistry to be part of the Virology Science and Technology Institute of the Philippines or VIP.
Department of Science and Technology (DOST) Undersecretary for Research and Development Rowena Cristina L. Guevara (Manila Bulletin File Photo)
DOST Undersecretary for Research and Development Rowena Cristina L. Guevara made the call during the “VISION 2021: Virology Science and Technology Institute of the Philippines, Information, Opportunities and Networking” webinar initiated by the DOST’s National Research Council of the Philippines (NCRP).